Roche's $1.4 billion acquisition of Igen left Igen shareholders gleeful and some Roche observers a bit wary of the high price tag. But by ending protracted litigation between the two companies, the deal protects one of Roche Diagnostics' core franchises, the central laboratory business.
Roche 's $1.4 billion deal to buy Igen International Inc. [See Deal] left Igen shareholders gleeful to say the least and some Roche observers a bit wary of the high price tag and generous terms. But by ending protracted litigation between the two companies, the deal protects one of Roche Diagnostics ' core franchises, its centralized laboratory business.
The purchase also underscores Roche's willingness to pay dearly for coveted technology that will lead to leadership in an important...
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
